• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Immunotherapy 2.0: Dr Patricia Salber Interviews Dr Harold Burstein

Podcast

The field of immunotherapy is a work in progress and researchers are now expanding the use of this treatment and doing a better job of identifying the patients that will benefit the most from it.

During the latest Managed Care Cast, Patricia Salber, MD, MBA, of The Doctor Weighs In, interviews Harold J. Burstein, MD, PhD, an oncologist with the Dana-Farber Cancer Institute, about immunotherapy 2.0, which was named the advance of the year by the American Society of Clinical Oncology (ASCO). This is the second year in a row that ASCO named immunotherapy the advance of the year; however, immunotherapy 2.0 acknowledges the expanding use of immunotherapy.

According to Burstein, the report recognizes that immunotherapy is a work in progress and that researchers are now doing a better job of identifying patients and tumor subsets that will benefit the most from this therapy. During the interview, Burstein and Salber also discuss toxicities related to immunotherapy and paying for the treatment.

Listen below or through one of these podcast services:

iTunes: http://apple.co/2eYWTss

TuneIn: http://bit.ly/2gv7iwj

Stitcher: http://bit.ly/2gCqtFg

Related Videos
Wanmei Ou, PhD, vice president of product, data analytics, and AI at Ontada
Glenn Balasky, executive director of the Rocky Mountain Cancer Center.
Corey McEwen, PharmD, MS
dr linda bosserman
dr andrew leitner
Glenn Balasky during a video interview
dr joseph alvarnas
dr joseph alvarnas
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.